Beyondspring Inc
BYSI
View Detailed Chart
1.887USD
-0.063-3.25%
Market hours （ET）Quotes delayed by 15 min
76.08MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.25%
5 Days
+3.10%
1 Month
+7.81%
6 Months
+12.98%
Year to Date
+15.75%
1 Year
-11.00%
View Detailed Chart
TradingKey Stock Score of Beyondspring Inc
Currency: USD Updated: 2025-11-05Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beyondspring Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Beyondspring Inc Highlights
StrengthsRisks
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Undervalued
The company’s latest PE is -69.10, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.85M shares, decreasing 1.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 11.60K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.58.
Beyondspring Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Beyondspring Inc Info
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Ticker SymbolBYSI
CompanyBeyondspring Inc
CEODr. Lan Huang, Ph.D.
Websitehttps://www.beyondspringpharma.com/en/
Related Instruments
+0.35%
+0.12%
+0.11%
+3.53%
+0.81%
+1.33%
-2.00%
-2.68%
+0.20%
+0.87%
+0.53%
+0.19%
-0.65%
-0.27%
+0.15%
+0.75%
0.00%
+1.39%
+2.31%
-0.17%Popular Symbols
